Financing, Equity Capital Markets

Neoleukin Therapeutics

12/19
|
$86.2 Million
Piper Sandler served as bookrunner for Neuleukin Therapeutics, Inc. on a confidentially marketed follow-on offering
Sub-Type
CMFO
Sub-Sector
Biopharma